EyePoint's DuraVu Inflection: Phase III Readouts and the IL-6 Differentiator

A Pivotal Quarter Before the Readout

EyePoint enters a critical window. In Q1 2026, management reiterated that top-line data from LUGANO and LUCIA—the two identical Phase III trials for DURAVYU in wet AMD—will arrive mid-year. On the call, Jay Duker highlighted the company's position: “We remain on track to deliver these Phase III top line data in wet age-related macular degeneration or wet AMD, beginning mid-year, positioning us to potentially be the first to market among all current investigational sustained release programs.” — Jay Duker, President and Chief Executive Officer · 2026-05-06 The LUGANO readout is arguably the most important catalyst in EyePoint's history, potentially transitioning it from a development-stage biotech to a commercial company.

We have strong conviction that the upcoming LUGANO and LUCIA readouts will catalyze our future transition into a fully integrated biopharmaceutical company.

What's changed this quarter is not just the timeline, but the narrative around the product's mechanism. The company unveiled peer-reviewed ARVO data showing vorolanib's ability to inhibit IL-6 signaling via JAK1—adding a third pathway to its established anti-VEGF and anti-PDGF activity. This multi-MOA angle is central to the DURAVYU story, especially for DME where IL-6 has long been implicated. As Jay explained: “The indirect effects, of course, number one is visual acuity... we hope to show that even if we're non-inferior and equivalent to Eylea, but we can provide the benefit earlier with fewer injections.” — Jay Duker, President and Chief Executive Officer · 2026-05-06 This echoes a theme from our prior call where management noted: “There is substantial evidence in both wet AMD and DME that IL-6 plays a pathogenic role.” — Jay Duker, President and Chief Executive Officer · 2025-11-05 The DME program is also gaining traction; over one-third of patients are enrolled across COMO and CAPRI, and all 90 invited wet AMD investigators accepted participation. “We invited 90 of our wet AMD investigators to be investigators in the DME trials and all 90 accepted.” — Jay Duker, President and Chief Executive Officer · 2026-05-06 This patient centric design resonates because DME patients are often younger and work, making a 6-month therapy highly attractive.

Commercial Readiness and the Competitive Landscape

The company has been building commercial infrastructure, hiring a Chief Commercial Officer and expanding marketing, market access, and medical affairs teams. This commercial readiness is a recurring theme in 2026, with a real focus on launch preparation. Meanwhile, the competitive landscape is shifting; a competitor TKI readout earlier this year has changed the conversation. Jay framed it constructively: “This is not a zero-sum game. The TKIs are going into a multibillion-dollar market.” — Jay Duker, President and Chief Executive Officer · 2026-05-06 Mike Campbell pointed to persistent unmet need: “The #1 need in wet AMD treatments that is reported from ASRS is still durability even with VABYSMO and Eylea HD in the market.” — Michael Campbell, Role not explicitly stated, likely Senior Executive or Medical Affairs · 2026-05-06 That durability gap is precisely what DURAVYU aims to fill, and the supplementation rate—how often patients require rescue anti-VEGF injections—will be a key metric to watch in the upcoming data.

Financial Position and the Path Forward

Q1 financials showed a net loss of $85M and cash of $223M, funding operations into Q4 2027. But the burn is accelerating as Phase III and DME trials scale. Cash runway fell to 2.8 quarters—still enough to cross the wet AMD data, but the margin for error is thin. Management stresses disciplined investment, but the pivotal trials and the Northbridge manufacturing scale-up are pushing R&D spend higher (R&D up 23% yoy). The safety profile remains a strong pillar, consistent with previous trials. As management emphasized on the prior quarter call: “We are very comfortable with our safety. We have had no ocular or systemic SAEs attributed to our drug.” — Jay Duker, President and Chief Executive Officer · 2026-03-04

The next few months determine EyePoint's trajectory. A successful LUGANO readout, combined with the IL-6 angle and a growing commercial organization, sets the stage for a major re-rating. Conversely, any safety signal or supplement-rate surprise could trigger the opposite. Investors are watching the DSMB meeting in May and the eventual data release. As Jay summarized: “We are proud to be advancing DURAVYU as a potential first and best-in-class option in the 2 largest retinal disease markets.” — Jay Duker, President and Chief Executive Officer · 2026-05-06